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“My mental illness is like a skunk, 
People know very little about me 
But neither do they care to know, 
Interlinking lives can be enriching 
And much can be learned from one another, 
Fear from what has become as common knowledge 
Prevents them from any involvement whatsoever 
And even causes others to go out of their way 
For the single purpose of avoiding me.” 
 
Like a skunk by Barbara 
http://www.squidoo.com/voices_of_schizophrenia 
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Abstract 
 
 The general purpose of this dissertation was to explore and describe the global 
and specific aspects of neurocognition and cognitive functioning in a cross-
sectional, clinically representative group of outpatients with schizophrenia 
spectrum disorders, using healthy volunteers as a control group, whenever feasible. 
 Study I analyzed and compared neurocognitive test profiles related to different 
levels of verbal learning performance among patients with schizophrenia spectrum 
disorders and healthy volunteers in order to identify the major predictors of 
category assignment. Approximately four out of ten patients had normal levels of 
verbal learning performance. Despite equivalent levels of verbal learning in 
comparison with healthy volunteers, the patients performed worse on all subtests 
with the exception of working memory. All patients also presented equally poor 
visuomotor processing speed despite their level of verbal learning performance, 
indicating global neurocognitive retardation in speed-related processing. 
 Study II assessed the relationship between the global assessment of functioning 
(GAF) subscales and neurocognitive test performance in a cohort of outpatients 
with schizophrenia spectrum disorders, based on gender. The GAF associations 
with composite cognition varied as a function of sex, suggesting a complex 
relationship between these variables. Furthermore, the results indicated that 
executive functioning may have a greater impact on the symptom and function 
profiles of male patients than on those of female patients. 
 Study III analysed and compared vigilance-related performance profiles of male 
and female patients with schizophrenia spectrum disorders, in and out of remission, 
against healthy volunteers. There was a sex-related difference in signal detection 
scores in the healthy volunteer group but not in the patient group. Also, perceptual 
sensitivity was shown to be significantly affected for patients of both sexes, but the 
ratio was almost two times larger for male patients, suggesting a larger 
neurocognitive decline in the male patient population. 
 Study IV elicited how people with schizophrenia spectrum diagnoses evaluate 
their own cognitive ability, with main focus on psychometrically validated 
cognitive improvement. The patients found it hard to evaluate their cognitive 
improvement as the demands in their daily life were low. Also, they tended to 
ascribe concentration problems to feelings of anxiety and restlessness, or claimed 
them to be a side-effect of antipsychotic medication. The patients still felt it 
meaningful to receive feedback on their improved test results as the information 
made them feel more proud and empowered. 
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Sammanfattning 
 
 Avhandlingens syfte var att undersöka och beskriva globala och specifika 
aspekter av neurokognition i ett tvärsnittsstudie av kliniskt representativa 
öppenvårdspatienter med schizofrenispektrum störningar. Friska frivilliga har 
använts som kontrollgrupp i vissa delstudier. 
 Delstudie I analyserade och jämförde neurokognitiva testprofiler hos 
psykospatienter och friska frivilliga utifrån tre nivåer av verbal inlärning. Syftet var 
att hitta andra kognitiva faktorer som bäst kunde förutsäga grupptillhörighet. 
Ungefär fyra utav tio patienter fanns ha normal verbal inlärningsförmåga. Trots 
detta presterade patienterna sämre än friska frivilliga på samtliga test utom det för 
arbetsminne. Samtliga patienter, oavsett nivån av verbal inlärning, hade likvärdiga 
svårigheter i test för visuomotorisk snabbhet. Resultaten indikerar på en global 
neurokognitiv nedsättning i tidsrelaterade mentala processer. 
 Delarbete II studerade sambandet mellan global funktionsskattning och 
neurokognition hos manliga och kvinnliga patienter med schizofreni-spektrum 
störningar. De olika aspekterna av global funktionsskattning hade olika samband 
med kön, vilket tyder på ett komplext samband mellan dessa variabler. Resultaten 
gav också indikation på att exekutiv funktion kan ha en större betydelse för mäns 
symptom- och funktionsprofiler än för kvinnors. 
Delarbete III analyserade och jämförde vigilans-relaterade prestationsprofiler hos 
friska frivilliga samt psykospatienter efter kön och remission. I friska frivillig-
gruppen fanns en könsrelaterad skillnad i signaldiskriminering, medan samma 
skillnad saknades i patientgruppen. Perceptuell känslighet var signifikant påverkad 
för båda könen, men skillnaden var betydligt större för män än kvinnor, indikerande 
på större neurokognitiv nedsättning hos män med schizofrenispektrum störningar. 
Delarbete IV studerade hur personer med psykossjukdomar skattar sin egen 
kognitiva förmåga mot bakgrund av validerad förbättring av kognitiva testresultat. 
Patienterna fann det svårt att värdera sin kognitiva förbättring då de upplevde 
vardagens krav som låga. De hade lättare att berätta om kognitiva svårigheter, och 
menade att koncentrationsproblem berodde på ångest och rastlöshet eller medicin-
biverkningar. Patienterna ansåg det dock värdefullt att få återkoppling om de 
förbättrade testresultaten som fick dem känna sig stolta och mer kapabla. 
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Chapter 1: Introduction 
 
 
Schizophrenia 
 
  Schizophrenia is a heterogeneous, multifactorial, complex biological and 
behavioral disorder, which manifests itself in cognitive dysfunction and other 
clinical symptoms. The disorder will not emerge without a congenital 
predisposition, but there are no guarantees as to who will develop the disease. Risk 
factors increase the chance of developing schizophrenia and protective factors 
decrease the chance (Green 2001, p.28). Risk factors can include adverse events 
early in life, for example maternal separation and social isolation, that via central 
stress dysregulation (Goel and Bale, 2009) profoundly affect brain development 
and adult behavior, thus contributing to the occurrence of psychiatric disorders in 
genetically predisposed individuals (Niwa et al, 2011). 
 
Neurodegenerative or neurodevelopmental disorder? 
 
 Determining the characteristics of schizophrenia is of singular importance for 
understanding the pathophysiology of the disorder and its treatments. The clinical 
heterogeneity of schizophrenia has given way to considerations that the symptoms 
may constitute groups of diseases of generally common phenotypic [for definition, 
see page 2] expression but of different underlying etiopathology (Buckley et al, 
2009). There has been much debate about whether or not schizophrenia is 
predominantly a neurodegenerative disorder or a neurodevelopmental disorder or 
incorporates elements of both (Andreasen, 2010; Archer, 2010). Neurodegenerative 
theories (Hulshoff Pol and Kahn, 2008) of schizophrenia posit that there are 
progressive structural changes in the brain after the debut of the illness, whereas 
neurodevelopmental theories (Fatemi and Folsom, 2009; Owen et al, 2011) posit 
that a brain insult takes place during the course of early normal development, 
disrupts developmental processes, and results in the various manifestations of the 
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illness. There seems to be a current tendency towards unifying models. Ho et al 
(2003) proposed that schizophrenia be called a “progressive neurodevelopmental 
disorder”. According to this model, schizophrenia occurs as a consequence of 
multiple aberrations in the process of brain development, with some occurring 
during fetal life or early childhood, whereas others occur during adolescence and 
young adulthood. The late neurodevelopmental mechanisms may continue to exert 
their damaging effects after onset and during the early years of the illness. 
However, the authors admit that the developmental neurobiological processes that 
explain these serial changes remain a puzzle. Gupta and Kulhara (2010) 
summarized that these theories are complementary rather than exclusive, because 
they can individually explain certain phenomena observed in the onset and course 
of schizophrenia, and put together, they can explain the onset as well as the course 
and outcome. According to Andreasen (2010), combining a recognition that 
abnormalities are present at onset (further evidence for neurodevelopment) with a 
recognition that changes also occur or continue after onset (neurodegeneration or 
neuroprogression) ceases to present problems. 
 
Endophenotypes 
 
 Another recent line of focus is the concept of endophenotypes. Genotypes are at 
the level of DNA base pairs and can be measured with techniques of molecular 
biology, whereas a phenotype represents observable characteristics of an organism, 
which are the joint product of both genotypic and environmental influences. 
Endophenotypes are described as internal phenotypes and may be 
neurophysiological, biochemical, endocrinological, neuroanatomical, cognitive, or 
neuropsychological in nature (Gottesman and Gould, 2003). They are seen as closer 
to genetic variation than are clinical symptoms of schizophrenia, and are thereby 
closely linked to heritable risk factors (Braff et al, 2007). Thus, endophenotypes are 
expected to be associated with the clinical disorder but not part of its diagnosis; 
heritable; present before the onset of active illness or during remission; co-
segregating with illness in families; and found in unaffected family members at a 
higher rate than in the general population (Jablensky, 2010). Endophenotypes are 
quantitative measures that reflect genetically influenced stable changes in brain 
function (Courtet et al, 2011). For example, suicide could be categorized as a 
phenotype, gene coding for the serotonin receptor as a genotype, and the tendency 
to impulsive-aggressive behavior as an endophenotype (Mann et al, 2009). 
 Neurocognitive findings in schizophrenia may qualify as endophenotypes. For 
example, working memory has been found to be compromised in patients with 
schizophrenia (Horan et al, 2008), and researchers have identified gene and 
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chromosomal regions possibly involved in working memory (Paunio et al, 2004). 
Combining cognitive tasks such as working memory with imaging techniques, 
thereby localizing the deficit to a particular neural circuit, refines the 
endophenotypical level of analysis more than measuring working memory 
performance alone as measured by neuropsychological testing (Gottesman and 
Gould, 2003; Thaker, 2007). On the other hand, it has to be proven that the studied 
dysfunction is differential for a particular subtype of psychosis, i.e., schizophrenia, 
only. Some studies suggest that neurocognitive dysfunction can be a vulnerability 
factor to psychotic disorders in general, rather than specific of schizophrenia (Mulet 
et al, 2007). Others claim that while cognitive deficits are present in all psychotic 
disorders, they are most severe and pervasive in schizophrenia and least pervasive 
in bipolar disorder and mania (Zanelli et al, 2010). 
 
Cognition in schizophrenia 
 
 In the 1990’s, the phenomenology of schizophrenia expanded beyond symptoms 
altogether, to include a strong emphasis on neurocognitive aspects of schizophrenia 
(Green and Nuechterlein, 1999). Cognitive deficits are since then accepted as a core 
feature of schizophrenia, rather than an epiphenomenon of the illness state 
(Jablensky, 2010). It has been proposed that the well-known diversity of 
schizophrenia in terms of functional outcome and recovery from the illness is best 
characterized by cognitive deficits, not by the classical symptoms (Reichenberg, 
2010). 
 
 Patients with schizophrenia perform as a group 1½ to 2 standard deviations 
below healthy controls on various neurocognitive tests (Keefe, 2008). Seven 
separable cognitive factors have been replicable across studies and represent 
fundamental dimensions of cognitive deficit in schizophrenia: speed of processing, 
attention/vigilance, working memory, verbal learning and memory, visual learning 
and memory, reasoning and problem solving, and verbal comprehension 
(Nuechterlein et al, 2004). There is compelling evidence that cognitive deficits are 
significantly correlated with impairments in activities of daily life (Jablensky, 
2010), but still, as Keefe (2008) points out, psychiatrists rarely consider cognitive 
function in their evaluation of patients with schizophrenia. One of the reasons 
behind this is that cognitive functioning is best assessed by neuropsychological 
testing, which requires a trained psychologist. Several studies (Good et al, 2004; 
Hofer et al, 2007; Keefe, 2008) have suggested that clinical rating of cognitive 
symptoms, using for example the PANSS (Positive and Negative Syndrome Scale: 
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Kay et al, 1989), is not suitable to replace neuropsychological testing in 
schizophrenic patients, irrespective of the stage of the illness. 
 
 There may be some episode-related cognitive deterioration. Controlling for 
premorbid IQ, Eberhard et al (2003) showed that on average, schizophrenic patients 
had lost one standard deviation in most cognitive tests, except for vocabulary, after 
their first psychotic episode. This drop remained static but for two 
neuropsychological indices: simple reaction time and verbal short term memory, 
that deteriorated by new episodes. In contrast, an Israeli study (Caspi et al, 2003) 
found no changes between a first assessment while in good mental health (draft 
board aptitude assessment) and a second assessment following the manifestation of 
the first psychotic episode. However, the patients performed worse than the healthy 
comparisons on both assessments. According to the authors, the results indicate that 
most of the cognitive impairment exhibited by first-episode schizophrenic patients 
precedes the first psychotic episode. A meta-analysis of 53 longitudinal studies of 
cognition in schizophrenia (Szöke et al, 2008) even indicated that for some 
cognitive domains, improvement is possible after the onset of the disorder. Rund 
(2009) summed it up in pointing out that there is an established decline in 
neurocognitive functioning prior to and in connection with the onset of illness, but 
there is currently no convincing evidence that there is a cognitive decline after 
onset of illness.  
 
Global versus specific deficits 
 
 One of the controversies that developed in the early years of research on 
cognition in schizophrenia was, and still remains, whether or not all 
schizopsychotic patients perform equally poor on every cognitive test that they 
attempt, producing a global intellectual deficit, or have greater deficits in one or 
more critical aspects of functioning. A related question is whether all patients with 
schizophrenia have a specific deficit, similar to all patients with Alzheimer’s 
disease expressing a memory deficit (Harvey and Sharma, 2002, p.5). This debate 
can be tied to the debate about neurodegeneration versus neurodevelopmental. 
Deficits that are stable could reflect a possibly neurodevelopmental condition, 
while others could be state dependent, fluctuating with psychopathology (Brewer et 
al, 2006). Green (1998, p.53) concluded that patients with schizophrenia have 
deficits in multiple domains, but a single generalized deficit fails to account for the 
range and pattern of findings. 
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 Alternatively, there can be multiple subtypes of patients with schizophrenia, each 
with their own characteristic pattern of neurocognitive deficits (Green, 1998, p.51). 
Attempts to find subtypes have been based on symptom profiles (Seltzer et al, 
1997), degree of memory impairment (Abi-Saab et al, 2005; McDermid Vaz and 
Heinrichs, 2002), skills on problem-solving tests (Horan and Goldstein 2003), and 
general intelligence (Potter and Nestor, 2010), just to name a few.  
 
Gender aspects 
 
 The existence of gender specificity in different aspects of schizophrenia has been 
disputed and the conclusions have been conflicting, if not confusing. The 
inconsistency may be due in part to methodological and/or cultural artifacts. 
Plausible results may be affected, for example, by the duration and phase of the 
illness. A Danish study (Køster et al, 2008) of 269 persons with first episode 
psychosis, with a follow-up two years later, showed women to have a longer 
duration of illness before treatment and more affective symptoms, while men had 
more negative symptoms and were more socially isolated. A review (Large and 
Nielssen, 2008) of studies of the duration of psychosis in schizophrenia spectrum 
disorders from high-income countries showed men to have a longer duration of 
psychosis than women. In contrast, most studies from lower-income countries 
showed the opposite trend, with women having a longer mean duration of 
psychosis than men. 
 The best replicated sex-related difference in schizophrenia is the tendency for 
male patients with schizophrenia to manifest the disease around five years earlier 
than female patients with schizophrenia. This observation may be due to the sex-
related differences found in the structural abnormalities that occur in schizophrenia, 
with greater abnormalities found in male brains (Arango et al, 2008). These 
differences may exist already at a genetic level. A study by Schumacher et al 
(2009) showed sex-specific effect in genetic linkage in a large European population 
of schizopsychotic patients, with different markers for men and women. 
 
 Few studies have addressed gender differences in premorbid cognitive 
performance. An Israeli historical-prospective study (Weiser et al, 2000) showed 
that in apparently healthy adolescents who will develop schizophrenia in the future, 
premorbid cognitive performance was poorer in women, as compared to men. The 
follow-up period was up to age 26, by which age more men than women will have 
manifest schizophrenia. The authors concluded that it is possible that the early 
onset women identified in their study have a particularly severe form of illness. 
Mortiarty et al (2001) studied a group of poor outcome patients with lifelong 
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schizophrenia and found no gender differences in cognitive functioning. Their 
findings suggest that the association of cognitive deficits with gender may be found 
only in patients with better functional outcome. This finding could imply that 
differences in gender may reflect a different etiology for the illness and for 
associated cognitive impairments as well. Nevertheless, there remains one critical 
aspect to gender differences that must be borne in mind throughout: that any 
eventual between-gender differences are generally overshadowed hugely by the 
enormity of the within-gender differences. For example, epidemiological evidence 
from the Australian National Study of Low Prevalence (Psychotic) Disorders 
showed differences between women across the diagnostic groups to be more 
pronounced than differences between women and men within a diagnostic group 
(Morgan et al, 2008). 
 
Aims of the dissertation 
 
 The general aim of this dissertation was to explore and describe the global and 
specific aspects of neurocognition and cognitive functioning in a cross-sectional, 
clinically representative group of outpatients with schizophrenia spectrum 
disorders, using healthy volunteers as a control group, whenever feasible. 
 Study I analyzed and compared neurocognitive test profiles related to different 
levels of verbal learning performance among patients with schizophrenia spectrum 
disorders and healthy volunteers, in order to identify the major predictors of 
category assignment. 
 Study II assessed the relationship between the global assessment of functioning 
subscales and neurocognitive test performance in a cohort of outpatients with 
schizophrenia spectrum disorders, based on gender. 
 Study III analyzed and compared vigilance-related performance profiles of male 
and female patients with schizophrenia spectrum disorders, in and out of remission, 
against healthy volunteers. 
 Study IV elicited how people with schizophrenia spectrum diagnoses evaluate 
their own cognitive ability, with main focus on psychometrically validated 
cognitive improvement. 
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2 
Chapter 2: Summary 
 
 
 All data collected and analyzed in this dissertation comes from a wider research 
project called the Clinical Long-Term Investigation of Psychosis in Sweden 
(CLIPS). It is an ongoing, long-term naturalistic follow-up study of persons with 
schizophrenia spectrum disorders. The CLIPS study was initiated by the 
Department of Psychiatry, NU Health Care in Trollhättan, Sweden. During the 
baseline years 2000 to 2004, a research team of one psychologist and three nurses 
collected data from all eleven outpatient centres in the catchment area (with a 
population of approximately 272 000). From the year 2005 and on, data in CLIPS is 
annually collected from all outpatient centres by the local staff of nurses, 
occupational therapists and psychologists. 
 
Patient population 
 
 The outpatient settings in the NU Health Care catchment area have a population 
of about 670 patients with the diagnoses schizophrenia, schizoaffective disorder or 
delusional disorder according to DSM-IV and ICD-10. Out of the total number, 516 
patients were considered to be in a stable phase of the disorder as assessed from the 
patients’ medical records and observations of the psychiatric personnel, personnel 
from the community psychiatry and relatives. These patients were not presenting 
co-morbidity of other symptoms, such as dementia, that could influence the result. 
In total, 284 patients volunteered for the investigation and were presented with an 
extensive clinical test and interview battery, including study of their medical 
records. After 20 patients had been excluded due to having other diagnoses than 
those allowed, 264 patients remained. Of these, 233 had completed at least one of 
the neurocognitive tests administered. Missing value analysis resulted in a final 
group of 196 patients with complete results from all neurocognitive testing. One of 
these patients had completed only the neurocognitive testing with no other 
evaluations made. 
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Healthy volunteer population 
 
 The healthy volunteers originated from a standardization study conducted by 
undergraduate students at Karlstad University, Sweden, during the spring semesters 
of 2004 and 2005. Recruitment of healthy volunteers was carried out through direct 
contact with employees of various organizations, university students, pensioners, 
and through advertisements in the local newspapers. A heterogeneous population 
with regard to sex, age and education was sought after. All subjects were informed 
that their participation was anonymous and on a volunteer basis and that all the 
material collected would be treated with complete confidentiality. Each participant 
was tested singly over an interval of about one hour. All experimental testing was 
performed by altogether eight undergraduate psychology students, all of whom had 
completed a basic course in application of the neuropsychological test battery. A 
standardized procedure was observed carefully by each of the experimenters. Ten 
persons were excluded from the original group of 302 subjects: six persons who 
reported suffering from mental illness, and four persons who had a close relative 
with psychosis. After missing value analysis, 26 persons were removed from the 
group, reducing the healthy volunteer group to 266 persons. 
 
Instruments 
 
Neuropsychological tests 
 
 The patients were tested with a semi-computerized neuropsychological test 
battery, the Cognitive Performance Indicator, CPI. CPI was constructed in the late 
1990’s by Michael Green, Phil Harvey and Håkan Nyman for Janssen AB in 
Sweden for use in clinical trials and gives an overview of important cognitive 
functions in patients with schizophrenia. It consists of seven classical 
neuropsychological tests, six that measure aspects of cognition known to be 
reduced in the course of schizophrenia, plus one that estimates the subjects’ 
premorbid level of functioning. The tests were administrated in a standardized 
order (as presented below). The patients received immediate, individualized 
feedback on their test results. The results were immediately entered into in a 
database. 
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Verbal learning and memory 
 
 The Rey Auditory Verbal Learning Test (RAVLT) is a commonly used clinical 
measure of verbal learning and memory (Rey, 1964; Schmidt, 1996) that measures 
immediate memory span, provides a learning curve, reveals the presence or absence 
of learning strategies, elicits retroactive and proactive interference tendencies and 
tendencies to confusion or confabulation on memory tasks, measures both short-
term and longer-term retention following interpolated activity, and allows for a 
comparison between retrieval efficiency and learning (Lezak, 1995, p. 438). 
RAVLT consists of a 15-item word list that is presented five times, always in the 
same order, with an assessment of recall immediately after each presentation. 
Thereafter an interference list is presented, followed by a request to recall the 
original list without further presentation of the original list words. Finally, a 
delayed recall test is presented after 20 minutes. The RAVLT total score (the 
number of words correctly recalled, summed across the five immediate recall trials) 
was used as a measure of verbal learning. 
 
Attention/Vigilance 
 
 The Continuous Performance Test – Identical Pairs version (CPT-IP) is a 
computerized vigilance test (Cornblatt et al, 1988; Rosvold et al, 1956), presented 
in monochrome mode on a laptop computer. 450 stimuli (four-digit numbers) were 
presented in three sequences or ‘blocks’, with 150 stimuli in each. Stimuli were 
flashed on the computer screen at a constant rate of one per second, with a stimulus 
‘on’ time of 50 milliseconds. The target stimulus was the second of a pair of 
consequential identical numbers. Subjects were instructed to keep the left mouse 
button pressed down until the target stimulus appeared whereby they were to 
release the mouse button and quickly press it down again. All trials were 
continuously administered at a constant pace, with no formal breaks between the 
blocks. The total d’ score (a measure of perceptual sensitivity or attentional 
capacity, i.e. the participants ability to discriminate targets from non-targets) for the 
450 trial condition was used as a measure of vigilance. 
 
Speed of processing 
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 The Trail Making Test, originally part of the Army Individual Test Battery, is one 
of the most widely used and most sensitive brief examinations for brain impairment 
(Reitan, 1958). In Part A (TMT-A), subjects are required to join consecutive 
numbers with paper and pen under the pressure of doing the task as rapidly as 
possible. The test was scored as introduced by Reitan (Lezak, 1995, p. 381). The 
time to completion (in seconds) for the Part A condition was used as a measure of 
visuomotor processing speed/efficacy. Note that the scales are inverted, as lower 
scores stand for better performance. 
 
Cognitive flexibility 
 
 In Trail Making Test Part B (TMT-B), subjects are required to alternate between 
two sets, connecting numbers and letters with paper and pen under the pressure of 
doing the task as rapidly as possible. The test was scored as introduced by Reitan 
(Lezak, 1995, p. 381). The time to completion (in seconds) for the Part B condition 
was used as a measure of cognitive flexibility. Note that the scales are inverted, as 
lower scores stand for better performance. 
 
Working memory 
 
 The Letter-Number Sequencing (LNS), now a supplementary subtest in the 
Wechsler Adult Intelligence Scale-Third Edition (WAIS-III) (Wechsler, 1997), is 
often used for assessment of auditory working memory performance (Gold et al, 
1997). It requires the subjects to sort out letters from numbers within a row of 
alternating letters and numbers that are read to them, and to separately recall the 
letters and numbers in successive order. The subjects can either pass or fail on each 
trial. The number of trials on which the subjects were successful in producing the 
information correctly was used as a measure of working memory. 
 
Verbal facility 
 
 The Vocabulary subtest from the Wechsler Adult Intelligence Scale-Revised 
(WAIS-R) has been identified as the single best measure of both verbal and general 
mental abilities (Wechsler, 1981). The subject is asked the meaning of words, 
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arranged in order of difficulty, and their explanation is given 0, 1 or 2 points. The 
sum score was used as a measure of verbal facility. 
 
Executive function 
 
 The Wisconsin Card Sorting Test (WCST) has increasingly been employed as a 
clinical neuropsychological instrument and can be considered a measure of 
executive function (Heaton et al, 1993). The WCST consists of four stimulus cards 
and 128 response cards that depict figures, colors, and numbers. The subject is 
instructed to match each consecutive card from the deck with one of the stimulus 
cards by pressing a computer key. A message on the computer screen tells the 
subject whether each response is right or wrong. Once the subject has made a 
specified number of consecutive correct matches to the initial sorting principle, the 
sorting principle is changed without warning. The WCST proceeds in this manner 
through a number of shifts in sorting principle among the three possible sorting 
categories. The computer program calculates the test scores. The total number of 
completed categories was used as a measure of executive functioning. 
 
Clinical rating scales 
 
Global functioning 
 
 The Global Assessment of Functioning (GAF) is used to evaluate overall severity 
of psychiatric disturbance. It combines evaluation of symptoms as well as 
relational, social, and occupational functioning on a single axis. The rating does not 
include impairment in functioning due to physical or environmental limitations 
(APA, 1987). The scale runs from 1 to 100 and is divided into 10 equal parts 
providing defining characteristics, both symptoms and social functioning, for each 
10-point-interval. A low rating reflects worse symptoms and a poorer level of 
functioning, whereas a high rating reflects less symptoms and a better level of 
functioning. As the two GAF assessments measure different aspects of a patient’s 
condition, at times they provide a large difference in the scores in either direction. 
This situation caused the Norwegian administration to split the GAF scale into one 
symptom and one function score in 1998 (Pedersen et al, 2007), thereby 
introducing the split version of the GAF (the Split-GAF). The Split-GAF 
instrument is common in psychiatric clinical practice in Sweden and is applied in 
this dissertation. 
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Remission 
 
 Remission was defined through the application of an adapted Swedish translation 
of The Positive and Negative Syndrome Scale (PANSS) (Kay et al, 1987; 
Lindström et al, 1994), a structured clinical interview for schizophrenia, whereby 
eight chosen items, representing core symptoms diagnostically characteristic for the 
condition (delusions, unusual thought content, hallucinatory behavior, conceptual 
disorganization, mannerism/posturing, blunted affect, passive/apathetic social 
withdrawal, lack of spontaneity and flow of conversation), should be reduced to 
such an extent (a value not exceeding 3 points out of maximum 7 points) as to be 
solely regarded as mild without affecting the individual’s level of functioning 
(Andreasen et al, 2005; Helldin et al, 2007). The criteria of the condition having 
remained stable for at least six months could not be applied in this thesis, as no 
previous systematic assessments had been made. 
 
Ethics and consent 
 
 The CLIPS study was ethically approved in 1999 under its original study name 
RIS-SWE-21. The procedures followed were in accordance with the standards of 
the Ethical Research Committee at the University of Gothenburg, and with the 
latest revision of the Helsinki Declaration of 1975. When recruited, the participants 
received both oral and written information about the study. All participation in the 
study was preceded by written informed consent. In the cases a subject gave an oral 
consent but did not want to sign the form, the subjects case manager witnessed the 
oral consent and signed the form for the subject. All participation was on a free 
volunteer basis and could be terminated whenever the subject so wished and 
without having to provide any rationale, with no consequences for the subjects 
treatment. On completion of the investigation, each participant was awarded a 
raffle ticket (worth 50 Swedish crowns, about 5 Euro). 
 This study was supported in part by unrestricted grants from Janssen AB, 
Sollentuna, Sweden. It is hereby stated that no conflict of interest between all 
parties concerned exist. 
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Study I 
 
Participants 
 
 196 outpatients (116 men, 80 women) with schizophrenia spectrum disorders 
between the ages of 19 and 74 years (46.31 ± 11.76) and 196 healthy volunteers (78 
men, 118 women) from 20 to 80 years (47.81 ± 18.09) participated in this study. 
64.8 % of the patients were diagnosed with schizophrenia, 22.4 % with 
schizoaffective disorder and 12.8 % with delusional disorder. All but nine patients 
were on antipsychotic medication, with one of the nine prescribed medication the 
patient did not take. Five patients were about to be released from a psychiatric ward 
at the time of the testing; the others were living in the community. 
 The healthy volunteer group was reduced from 266 persons to 196 persons in 
order to match the size of the patient group. Before reducing the group size, all 
healthy volunteers with low scores on the main parameter RAVLT were saved, as 
there were only 27 of these in the whole volunteer group. Thereafter, a 
supplementary random selection was made in order to obtain a total group size of 
196 healthy volunteers. 
 
Design 
 
 The main purpose of this study was to identify major predictors of verbal 
learning category assignment in patients with schizophrenia spectrum disorders 
relative to that of healthy volunteers. The participants were examined with the 
RAVLT, along with the six other neurocognitive tests in CPI. The dependent 
variables were the measures from the six neurocognitive instruments. Verbal 
learning performance level and group (patients/healthy volunteers) were used as 
grouping variables. The main variable emerged during an unpublished pre-study 
when all neurocognitive variables were entered into the multivariate analysis data 
program SIMCA-P (by Umetrics), and verbal learning turned out to have the 
highest variable importance. In order to produce the main variable ‘verbal learning 
performance level’, the schizopsychotic and healthy volunteer groups were 
combined into one single group of 392 persons. The total number of words 
correctly recalled, summed across RAVLT trials I through V, were used as a 
learning summary score. This summary score is widely used (Schmidt, 1996), has 
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good test-retest reliability (Geffen et al, 1994), has been shown to discriminate 
mixed groups of neurological patients from normal subjects (Powell et al, 1991), 
and memory impairment from memory intact patients (Rosenberg et al, 1984; Ryan 
and Geisser, 1986). The RAVLT summary scores for the combined group were 
converted into standardized scores by the statistics program. The combined group 
scores were then divided into three subgroups (high-level, medium-level, low-
level) with -/+ 0.5 standard deviations as fixed markers. These markers was chosen 
according to Harvey and Sharma (2002, p.17), who have defined 0.5 to 1.0 standard 
deviations below mean as representing a mild level of cognitive deficit. The three 
levels of verbal learning performance were then analyzed for predictor variables. 
 
Instruments 
 
 All participants had been tested with the CPI test battery. In this study, the 
RAVLT total score was solely used to form the main variable ‘verbal learning 
performance level’. 
 
Statistics 
 
 A comparison of background variables (sex, education and civil status) for the 
patient group and healthy volunteer group were conducted with Mann-Whitney U-
test and t-test. In order to analyze the effect of age and education on verbal learning 
performance, one-way analysis of variance (ANOVA) and chi-square were used. 
Multivariate analysis of variance (MANOVA) was used to compare the effect of 
verbal learning performance level, study group and sex on the combined cognitive 
test variable. In order to identify the best combination of cognitive variables to 
predict the level of verbal learning performance, discriminant function analysis was 
conducted separately for each study group and each level of verbal learning 
performance. The Mahalanobis distance method was used in the analyses, which 
were then cross-validated with Press’s Q test. 
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Results 
 For distribution of schizopsychotic patients and healthy volunteers in the three 
levels of verbal learning performance, see Figure 1. 
 The general results showed the healthy volunteer group to have better cognitive 
function than the schizopsychotic patient group in all domains except working 
memory. Men across the groups had better vigilance then women, whereas women 
across the groups had slightly better executive function than men. Comparing the 
different levels of verbal learning performance across the groups, the higher level 
had superior performance and the lower level inferior performance in all domains 
except visuomotor processing speed/efficacy, where no effect of verbal learning 
level was found. 
 
 When analyzing the predictors for group membership, the best predictor of the 
level of verbal learning performance in the patient group was working memory. In 
the healthy volunteer group, working memory was also found to be the best 
 Schizopsychotic patients
 Healthy volunteers
Study group
Figure 1. Distribution (in percent) of schizopsychotic patients and
healthy volunteers in the three levels of verbal learning performance.
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predictor, paired with cognitive flexibility. Looking to predict the level of verbal 
learning performance across the patient and healthy volunteer groups, the higher 
level was predicted by cognitive flexibility, and to some degree even executive 
functioning. The intermediate level was also best predicted by cognitive flexibility, 
and secondly by vigilance. The lower level was predicted by both vigilance and 
executive function, and to some degree even verbal facility. 
 
Study II 
 
Participants 
 
Subjects were 195 medicated outpatients with a diagnosis of schizophrenia, 
schizoaffective disorder or delusional disorder who had completed all aspects of the 
relevant parameters of the investigation. 59 % of the sample were men and 41 % 
were women. The average age of the male patients was 44.11 ± 10.48 years, and 
the average age at their first psychiatric hospital registration was 28.11 ± 9.12 
years. The average age of the female patients was 49.39 ± 12.87 years, and the 
average age at their first psychiatric hospital registration was 32.36 ± 13.16 years. 
Five patients (three males and two females) were about to be released from a 
psychiatric ward at the time of the testing; the others were living in the community. 
 
Design 
 
 The main purpose of this study was to assess the gender-based relationship 
between GAF and neurocognitive test performance in a cohort of outpatients with 
schizophrenia spectrum disorders. The hypothesis was that a gender effect would 
be found.  Three main variables were used: the two GAF subscales and a 
composite cognition score that was created from the CPI. These three were the 
main dependent variables. The dependent variables were analyzed for gender 
effects and the relationships between the variables were investigated by gender. 
Finally, a separate analysis was employed to determine if the underlying 
neurocognitive measures in the composite cognition score had a predictive, gender-
related value on the GAF subscales.  
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Instruments 
 
 The participants had been tested with the CPI test battery and evaluated with the 
GAF. 
 
Statistics 
 
 All statistical analysis was performed on the Statistical Package for the Social 
Sciences (SPSS) version 15.0 for Windows. The composite cognition score was 
created by transforming individual test scores to z scores using the patient sample 
and then averaging across tests (Nuechterlein et al, 2008). Independent-samples t-
test was used to check for gender differences in the main variables. Stepwise 
multiple regression analysis was used to assess the predictive value of GAF 
Symptom and GAF Function on composite cognition. Additional stepwise multiple 
regression analyses were run to check for the effects of the individual 
neurocognitive tests against GAF Symptom and GAF Function. All variables were 
entered into separate analyses for men and women. 
 
Results 
 
 A comparison of GAF Symptom, GAF Function, and composite cognition scores 
between men and women showed no significant difference. Correlating these 
scores to each other, however, unearthed marked gender differences, see Table 3. 
For male patients, GAF Symptom subscale showed only a negative correlation for 
cognitive flexibility, whereas GAF Function subscale showed a positive correlation 
for executive function and negative correlations for cognitive flexibility and 
composite cognition. For female patients, GAF Symptom subscale showed negative 
correlations for both cognitive flexibility and composite cognition, but positive 
correlations for vigilance, executive function, working memory and verbal facility, 
whereas GAF Function subscale showed only positive correlation for working 
memory. Taken together, the results of the correlation analyses show notably 
different relationships between GAF subscales and cognition with regard to gender. 
Stepwise multiple regression analysis showed better composite cognition to be 
predicted by higher function levels in male patients and lower symptom levels in 
female patients. Reversed, GAF Symptom scores were best predicted by cognitive 
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flexibility in male patients and verbal facility in female patients. GAF Function 
scores were best predicted by executive function in male patients and working 
memory in female patients. 
 
Table 3. Correlation indices (Pearson’s r, 2-tailed) between GAF subscales and 
cognitive variables for male and female outpatients with schizophrenia spectrum 
disorders. 
 
 
Variable 
GAF Symptom GAF Function 
Male 
patients 
(N = 115) 
Female 
patients 
(N = 80) 
Male 
patients 
(N = 115) 
Female 
patients 
(N = 80) 
Composite 
cognition 
 0.40* 0.32*  
Vigilance  0.31*   
Cognitive flexibility -0.24* -0.31* -0.26*  
Working memory  0.33*  0.31* 
Verbal facility  0.36*   
Executive function  0.30* 0.32*  
* p = 0.01 
 
Study III 
 
Participants 
 
 195 patients (115 men, age 44.43 ± 10.42 years; 80 women, age 49.41 ± 12.82 
years) were recruited from the CLIPS study. Applying the severity, but not the time 
component of the remission criteria proposed by Andreasen et al (2005), it was 
established that 37 % of the male patients had achieved remission, whereas 63 % 
male patients had not. Likewise, 53 % of the female patients had achieved 
remission and 47 % had not. All but nine patients (4 men, 5 women) were on 
antipsychotic medication, with one of the females prescribed medication she did 
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not take. Five patients (3 men, 2 women) were about to be released from a 
psychiatric ward at the time of the testing; the others were living in the community. 
 275 healthy volunteers (115 men, age 47.11 ± 17.63 years; 160 women, age 
47.66 ± 18.30 years) from the general population took part in a standardization 
study conducted by undergraduate psychology students at Karlstad University, 
Sweden. All volunteers completed the same neuropsychological test battery as the 
patient group. 
 
Design 
 
 The main purpose of this study was to analyze and compare vigilance-related 
performance profiles of male and female patients with schizophrenia, in and out of 
remission, to male and female healthy volunteers. With the earlier described eight 
items from the PANSS instrument as a starting point, it was established which 
patients had achieved remission severity criteria and which patients had failed to 
fulfil the criteria for remission. The d’ for the three blocks in CPT-IP were used as 
dependent variables. First, the impact of sex on vigilance was studied. Secondly, 
sex-related profile analyses were done with age as co-variate to determine whether 
the patient group and the volunteer group had different performance over the three 
blocks in CPT-IP, and whether remission had an effect on vigilance test 
performance profiles. 
 
 
Instruments 
 
 All participants had been tested with the CPT-IP, and the patient group was also 
evaluated with the PANSS for remission. As the focus was on serial performance 
profiles over the three CPT-IP blocks, the d’ for the total test was not used in this 
study. 
 
Statistics 
 
 Pearson’s chi-square test, Mann-Whitney U-test and t-test were conducted for a 
comparison of demographic variables. Within-sex-related differences in signal 
detection scores were calculated with one-way analyses of variance (ANOVA). 
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Repeated measures multivariate analyses of covariance (MANCOVA), with group 
and sex as between-subjects factors and age as covariate, were used to analyze 
performance profiles (Tabachnick and Fidell, 2007) over the three blocks of CPT-
IP in patients with schizophrenia spectrum disorders and healthy volunteers. The 
confidence intervals were Bonferroni adjusted. All statistical analysis was 
performed on the Statistical Package for the Social Sciences (SPSS Inc, Chicago, 
Illinois) software, version 15.0 for Windows. Alpha levels of 0.05 were used, but as 
the study was explorative, nearby levels are reported when of major interest. 
 
Results 
 
 The men in the healthy volunteer group had better test performance than men in 
the patient group. The same pattern applied to the women. Men had better signal 
detection scores than women, but only in the healthy volunteer group. There was no 
difference between male and female test scores in the patient group.  
 A specific vigilance test performance profile was found in the healthy volunteer 
group, with performance improving after the first block. No difference in 
performance across the three test blocks was found in the patient group, see Figure 
1. 
 
 
 
 
Figure 1. Performance profiles for d’ over the three blocks of CPT-IP for healthy male 
(HV-M) and female (HV-F) volunteers, and for male (SZ-M) and female (SZ-F) patients 
with schizophrenia spectrum disorders. 
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 Patients not in remission performed on a lower level than patients in remission. 
This remission-related difference in performance levels was somewhat stronger 
among male patients than female patients. On the other hand, female patients not in 
remission displayed worse performance during later stages of the vigilance test than 
male patients not in remission, see Figure 2. 
 
 
Figure 2. Performance profiles for d’ over the three blocks of CPT-IP for male patients 
with schizophrenia in remission (REM-M) and not in remission (NREM-M), and for 
female patients with schizophrenia in remission (REM-F) and not in remission (NREM-
F). 
 
Study IV 
 
Participants 
 
 As a part of the CLIPS investigation, the patients completed a 
neuropsychological test battery when entering the study, and were re-tested some 
years later. In spring 2010, 99 out of 296 patients had been re-tested, whereof 38 
patients at the largest outpatient centre. Out of these 38 patients, 24 had improved 
test results in one or more of the neuropsychological tests; simultaneously, 16 of 
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them had also deteriorated results in some of the tests. These 24 patients were 
considered eligible for inclusion in this study and were consecutively asked to 
participate in extra interviews until finally ten patients were accepted. The 
interviewed patients were aged between 31 and 63 years old. Seven of them were 
men, three were women. Seven of the patients were diagnosed with schizophrenia, 
two with schizoaffective disorder and one with delusional syndrome. The baseline 
tests were conducted about eight years prior to the interviews, and the latest re-
testing about two years prior to this study. Four of the patients had statistically 
significant improvement in one or two of the seven tests from test to re-test, while 
the rest of the patients had mixed results. 
 
Design 
 
 The main purpose of this study was to elicit how patients with schizophrenia 
spectrum diagnoses evaluate their own cognitive functioning, using a qualitative 
methodology so that novel knowledge could emerge and existing concepts might be 
examined in the light of the patients’ experiences. The main focus was on 
psychometrically validated improvement on cognitive testing. Schizophrenia 
spectrum patients who had been tested with the CPI twice and had improved test 
results on at least one of the neurocognitive measures were eligible for this study. 
The patients were interviewed with the help of an interview schedule that centered 
on the patients’ self- perceived cognitive functioning in everyday life and in the test 
situation. The main focus was how patients evaluated and explained their own 
cognitive functioning, and whether they had noticed any improvement in cognitive 
functioning. The semi-structured interviews were audiotaped and then transcribed 
verbatim. Interpretative Phenomenological Analysis (IPA) (Smith et al, 2003; 
Smith et al, 2009) was applied to further describe the patients’ experience of 
cognitive functioning in everyday life. The overall aim of IPA is to translate the 
themes into a narrative account, attempting to find interesting and essential points 
in the material, seeking to understand, rather than explain or predict, participants’ 
worlds, as they are revealed in narratives.  
 
Instruments 
 
 All patients had been tested with the CPI twice, about six years apart. Semi-
structured qualitative interviews were conducted about two years after the second 
testing. IPA was used for analysis of the data from the interviews. 
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Results 
 
 All patients could, in varying degrees, still remember how they perceived the 
neuropsychological test situation. All but one patient could also relate perceived 
difficulties in the testing situation to similar difficulties in their everyday life. 
Despite this, most of the participants had trouble trying to figure out what meaning 
the documented neurocognitive improvement had in their daily life. Some of the 
patients thought that any test improvement was just a random effect or simply 
mood-related. 
 Eight major themes emerged from the data. 
 
1. Fast processing strains learning, memory and attention 
 
 Tasks that require quick processing, for example the computerized vigilance test, 
strained the patients’ cognitive performance and could quickly become 
unmanageable. Even the list of random words in the verbal learning test was 
perceived as demanding, hindering one participant from using a compensatory 
strategy. This reminded some participants of how teachers had “thrown words at 
them” at school and how large amounts of information quickly overwhelmed them, 
leading to fatigue and a need to rest. Social situations were also perceived as 
demanding as they require concentrating on many things at once. 
 
2. The ability to concentrate is blocked by anxiety and adverse 
effects 
 
 Several participants described substantial problems with concentration in 
everyday life. These problems were ascribed to feelings of anxiety and restlessness, 
causing a sense of powerlessness in the participants. A few of the participants had 
problems with the paper-and-pen trail making tests which require visuomotor 
coordination. These participants complained about physical weakness and problems 
with coordinating their movements, claiming this to be a side-effect of 
antipsychotic medication. Some of the participants had such profound difficulties 
with concentration during the whole test situation that they did not perceive any 
improvement from baseline testing. 
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3. Non-demanding or unchanged daily life makes evaluation 
difficult 
 
 Several participants said that the demands in their daily life were so low in 
domains such as memory, attention, and problem solving that it was difficult to 
evaluate the actual degree of cognitive dysfunction or improvement. Many of them 
had worked before and compared their current life situation with their working life. 
A number of participants felt that any cognitive improvement would be observable 
only if the demands of daily life changed or increased.  
 
4. Test improvement was just a random effect or simply mood-
related 
 
 Some of the participants thought that any test improvement was just related to 
their general mood, how they had slept, or any other random cause. A few of the 
participants had not experienced any changes in their everyday lives since they 
entered the study. These participants found it hard to find any meaning in their 
improved test performances. One of them was satisfied with daily life remaining 
unchanged; another was depressed over persistent everyday difficulties. Some 
participants said that they had little knowledge about the tests they took or the test 
results. They thought that the results probably had some meaning, but they were 
uncertain about what it was. 
 
5. Problem solving strategies are sometimes successful 
 
 Some of the participants were aware of memory problems and aspired to 
compensate with paper-and-pen. They took notes in class, wrote down what to say 
on the answering machine, made a note of dates to remember, and wrote shopping 
lists. Most of the time these simple memory aids were sufficient, but sometimes 
they failed. Problem solving strategies worked better when the participant felt that 
life was more structured than before. 
 
6. Antipsychotic medication improves thinking 
 
 Most of the participants believed that antipsychotic medication was the main 
reason for the improved test results. At the same time, many of them were troubled 
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by adverse effects such as fatigue. Despite these complaints, almost all participants 
said that antipsychotic medication was a necessity that they experienced as helpful. 
Switch to medicines that had less adverse effects was perceived as one possible 
cause to improved test results. One participant thought his cognitive improvement 
was, besides new medication, due to changes in his everyday life having become 
more well-settled and tranquil than before. 
 
7. Cognitive improvement parallels a more full or tranquil life 
 
 Several participants described that their lives had become more active and 
meaningful since baseline testing. Some of them had started to work or study since 
their first test and thought that this might have had a positive effect on their 
cognitive functioning. Going back to work or working more hours than before 
improved finances and enabled having a hobby. Work also gave a sense of 
belonging to a group, being useful, and making an essential contribution. Other 
daily activities such as reading, crossword puzzles, and computer use were seen as 
possible causes to improved cognition. One of the participants said that he thought 
his test results had improved as he had “studied more” in the period between 
baseline testing and re-testing. Thanks to his studies, he felt his memory had 
improved. 
 
8. Feedback gives inspiration and empowerment 
 
 Despite that the meaning of the psychometrically improved test results was 
unclear for most of the patients, many of them talked about the meaningfulness of 
receiving information about the improvement. The patients saw the improvement as 
a confirmation on their own feeling of having better mental health than before. 
Patients reacted with joy or relief to the news. Some of the participants described 
how the news about improved cognition made them feel proud and empowered. It 
meant that they “maybe can manage something out there”. The results were felt as 
encouraging and gave “inspiration to fight” to achieve desired goals in life. Even 
one patient who initially described the neurocognitive tests as “shallow” said that 
the results gave him a little more self-confidence and made him dare to take a small 
step forward in some area of his life. 
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3 
Chapter 3: Discussion 
 
 
 The present research was designed to be an exploratory analysis of 
neurocognitive test profiles in a clinically representative population of patients with 
schizophrenia spectrum disorders. The study was performed in a naturalistic setting 
at the outpatient clinics the patients were enlisted at, and they were recruited 
through their case managers. The findings can be generalized to clinical reality. 
 
Impaired and unimpaired profiles 
 
 In comparison to healthy volunteers, schizopsychotic patients as a group will 
always perform worse than the healthy volunteer group on any given test (Palmer et 
al, 2009). However, anyone who has met and tested a large population of 
schizopsychotic patients will have noticed the substantial variability in their test 
performance. While there unquestionably is a large group of patients with low test 
results, there is also a group of patients that will pass on some of the tests, and still 
another group who will perform as well as the healthy volunteer group. This has 
been established in several studies (Abi-Saab et al, 2005; Badcock et al, 2005; 
Rund et al, 2006) and is replicated in Study I. Green (1998, p.51) points out in his 
book that the proportion of patients in this range depends on the severity of the 
patient sample and the selection of the cut-off score, but is often around 50 %. 
Thus, all patients are not equally impaired, suggesting the presence of at least two 
neurocognitive subgroups: impaired versus unimpaired. 
 Study I found 43.9 % of the schizopsychotic patients to have normal (average or 
high) levels of verbal learning performance. Does this imply that approximately 
four out of ten schizopsychotic patients function overall equal to normal controls? 
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Same, but still different 
 
 Despite equivalent levels of verbal learning in comparison with healthy 
volunteers, the schizopsychotic patients in Study I performed worse on all subtests 
with the exception of working memory. The connection between verbal learning 
and working memory may be expected, as research has indicated working memory 
capacity to be an important moderating variable of learning (Psychological 
Corporation, WAIS-III WMS-III technical manual, 2002, p. 7). This applies to both 
the patient and volunteer groups, as working memory was a significant predictor of 
verbal learning performance level in both groups. Higher scores on the working 
memory test were associated with higher verbal learning performance levels for 
both study groups. 
 
 Another finding was that the schizopsychotic high level verbal learning 
performers presented a level of vocabulary that was comparable with that of the 
healthy volunteers, which suggests that superior verbal learning might be facilitated 
by a good word comprehension. This level of verbal learning performance/level of 
vocabulary relationship seems applicable only to the patient group since no 
differences in the verbal facility of the volunteers, despite the level of verbal 
learning performance, existed. Vocabulary scores are thought to reflect the 
subjects’ socio-economic and cultural origins rather than their academic 
achievement (Lezak, 1995, p. 540). However, in this respect an initial inspection of 
the schizopsychotic patients showing high level verbal learning performance 
revealed no obvious demographic pattern that could account for this verbal 
learning/vocabulary connection. But despite similar capacity in verbal learning, 
working memory and vocabulary, the high verbal learning performance 
schizopsychotic patients did not perform on an overall level equal to the healthy 
volunteers. 
 
 All the schizopsychotic patients presented equally poor visuomotor processing 
speed/efficacy, despite their level of verbal learning ability, as no significant 
differences were found within the patient group. This finding indicates retarded 
visuomotor processing speed, which has been suggested to be a generalised 
characteristic of the schizophrenic process (Badcock et al, 2004). Thus, even 
patients with intact learning ability, working memory and vocabulary appear to 
share this global neurocognitive retardation in speed-related processing, although it 
may not always be perceived as a prominent feature but as more of a background 
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influence against which there may or may not be impairment in other specific 
domains. 
 
Gender as a subgroup 
 
 One notion underlying the reasoning behind the Split-GAF scale, i.e. one 
symptom and one function score, was the bidirectional differences in scoring 
(Pedersen et al, 2007). The findings in Study II lend further credence to that 
application of the instrument. According to Gaite et al (2005), the notion of GAF as 
a bidimensional index of functioning incorporates distinctions between clinical and 
sociofunctional dimensions. This approach leads to a further requirement of 
attending to symptom profiles and functional profiles in undertaking provision of a 
diagnosis (Archer et al, 2008; Palomo et al, 2008). The utility of the Split-GAF 
scale achieves further applicability with regard to the results pertaining to 
distinctions between male and female patients. On the one hand, composite 
cognition scores were predicted by GAF Symptom levels in the female patients; on 
the other hand, composite cognition scores were predicted by GAF Function levels 
in the male patients. The above pattern of results regarding GAF Symptom, GAF 
Function and Global Cognition suggests that there is a complex relationship 
between these variables. 
 
 In a meta-analysis by Ventura et al (2009), both neurocognitive functioning and 
functional outcome were found to be significantly related to negative symptoms, 
supporting a model in which negative symptoms partially mediate the relationship 
between these two variables. In their model, neurocognition was still a primary 
causal variable that influences outcome. Therefore, they proposed neurocognition 
to have both direct and indirect effects on functional outcome. 
 A study of the predictive validity of underlying cognitive variables in the 
composite cognition score suggested that, in addition to above, there may be a 
gender-specific difference in the neurocognitive components. Executive 
functioning may have a greater impact on the symptom and function profiles of 
schizopsychotic males than on schizopsychotic females. 
  
 A study by Urbanek et al (2009) found an aspect of executive functioning 
(conflict inhibition) to differ significantly between patients and controls. This 
difference mainly resulted from a gender-specific reduction of the conflict effect 
and the conflict ratio in schizophrenic men. The same variables were elevated, 
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though not significantly, in schizophrenic women. Executive control of attention is 
involved in self-regulation of cognitions and emotions. The executive network 
involves the anterior cingulate cortex and lateral prefrontal cortical regions and is 
modulated by dopamine, with individual variations in executive attention related to 
genetic polymorphisms in genes related to dopamine (Wang et al, 2005). Neuhaus 
et al (2007) proposed that dysfunctional anterior cingulated cortex activation during 
executive processing may be a neurophysiologic endophenotype candidate of 
schizophrenia. 
 
 Taken together, the consensus of these results implies that there appear to be one 
or more mediating factors between neurocognition and global functioning that 
remain unidentified. Gender is known to modulate the onset and therefore the 
clinical course of schizophrenia, but there is limited knowledge regarding whether 
gender also influences the cognitive and functional profiles, and if so, to what 
degree. And, might these differences vary over ethnicity and culture? Further 
research is needed to solve this issue, but it is certainly necessary to consider the 
relative contribution of sex/gender in determining the functional expressions of the 
etiopathogenesis of schizophrenia spectrum disorders. 
 
Are studies involving neurocognitive 
performance by different populations of 
schizophrenic patients comparable? 
 
 There are basic methodological differences between studies of neurocognition in 
schizophrenia, the first of them being the composition of the patient group. In 
classical randomized clinical trials there are extensive exclusion criteria. Together 
with commonly used multi-center study designs, the schizopsychotic patient 
population is highly selected and does not resemble the patients met in everyday 
clinical practice. A naturalistic, observational cohort approach on the other hand 
has fewer restrictions, and the participation retention is higher than in randomized 
clinical trials. 
 
 Even though the relationships between psychotic symptoms and neurocognition 
are usually quite modest in strength (Green, 1998, p.89), Study III showed that 
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male patients in symptomatic remission performed significantly better on a 
vigilance test than male patients not in remission. The same difference was not 
significant for female patients, but they did display some remission-related 
variability in their performance patterns. Thus, remission may play a significant 
role in interpreting the results of neurocognitive testing and should be taken in 
consideration when reporting these results. 
 
 Another issue is the choice of neuropsychological tests. Some studies use 
conventional neuropsychological tests, while others use modified or newly created 
tests. The included cognitive dimensions vary, making it difficult to compare 
results. More recently, the National Institute of Mental Health’s Measurement and 
Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiated 
the development of a consensus cognitive battery for clinical trials of cognition-
enhancing treatments for schizophrenia through a broadly based scientific 
evaluation of measures (Nuechterlein et al, 2008). Four out of the seven chosen 
domains (speed of processing, attention/vigilance, working memory, and verbal 
learning) are covered in the present study, while no tests within the other domains 
(visual learning, reasoning and problem solving, and social cognition) are used. The 
main reason is that the present study is not a clinical trial but a naturalistic, 
observational study that does not have the same time limit as clinical trials do. For 
clinical trials, high test-retest reliability is vital as retesting is done after a relatively 
short time span. 
 
 Nevertheless, as Jaeger et al (2006) indicated, conventional neuropsychological 
tests are polyfactorial, in that task performance is influenced by multiple cognitive 
operations, and all testing requires a basic capacity of attention, learning and 
memory. Hence, it is difficult to pinpoint exactly for which cognitive operations a 
low scoring subject may have a low level of functionality. 
 
Insight, from different perspectives 
 
 Self- and expert-rated clinical outcomes rely on different assumptions and differ 
markedly. Karow et al (2011) found that in only 18 % of the cases do patients with 
schizophrenia, relatives and psychiatrists agree in their assessments of remission. 
Furthermore, symptomatic remission as assessed by the standardized criteria plays 
a secondary role for patients and relatives in daily clinical practice. Good subjective 
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well-being was the most important for remission estimated by patients; good 
subjective well-being and symptom reduction by family members; and finally, 
better symptom scores, well-being and functioning by psychiatrists. The authors 
conclude that a more thorough consideration of patients’ and caregivers’ 
perspectives should supplement the experts’ assessment. 
 Likewise, Study IV found that patients with schizophrenia had difficulties trying 
to relate their cognitive test performance to their everyday life. Cognitive capacity 
seems to be validated by tangible changes towards a more comprehensive life, in 
general mental health or in daily functioning. Patients who had not had any positive 
change in their daily life in the period between test and re-test did not perceive any 
improvement in their cognitive functions, nor did they think that the test results had 
any effect on or meaning in their lives. In general, it was far easier for the patients 
to describe cognitive difficulties than cognitive improvement. However, this focus 
is not specific for patients with schizophrenia spectrum disorders. Bayard et al 
(2009) found that patients with schizophrenia, after controlling for level of 
depressive symptoms, did not express abnormally high cognitive complaints when 
compared to data gathered in healthy controls matched for age and education. As 
concluded by Medalia et al, specific education about cognitive symptoms may be 
necessary for compliance with cognitive remediation and/or cognitive enhancing 
medications. The results may endow the neurocognitive test battery a valuable 
psycho-educational instrument to facilitate patient functioning. 
 
Staging in schizophrenia spectrum disorders 
 
 The clinical staging model has been used to describe illnesses which develop in 
a complex way, such as cancer. Stages describe not only a particular point in the 
course of the disease, but also the appropriate treatment for that stage. A clinical 
staging model makes three key predictions: pathologic measures should be more 
abnormal in more severe stages; patients who progress between the stages should 
show change in the same pathologic measures; and treatment should be more 
effective in the earlier stages, as well as more benign (Wood et al, 2011). 
 It has been suggested that the model can be useful in planning the treatment of 
other complex illnesses such as schizophrenia, contributing to early identification, 
diagnosis, and treatment (Archer et al, 2010). The stages that have been proposed in 
the development of schizophrenia are the prodrome, the first episode, and the long-
term chronic phase (Agius et al, 2010). Staging may allow a more efficient 
integration of the biological, social and psychological vulnerability factors involved 
in development of mental illness into what may ultimately resemble a 
 32 
 
clinicopathological staging model (McGorry, 2010). Clinical staging of 
schizophrenia spectrum disorders is facilitated through the systematic 
neurocognitive performance profiles, so that comprehensive considerations of 
diagnosis, prognosis and treatment enjoy greater availability. The patient situation 
is complicated by a multitude of genetic predispositions, epigenetic forces, 
symptoms and syndromes, early-onset and prodromal phases, recurrences and 
relapses that remain to be solved, possibly through multicenter efforts (Archer et al, 
2011). Qualitative analyses derived from patients’ awareness/non-awareness of self 
provide a valuable ancilliary to neurocognitive profiles of clinical staging. 
 
Observations and impressions 
 
 Despite the time-consuming aspect of testing this singularly large population of 
patients, single-handed, the rare opportunity of personal access to a wide variety of 
schizopsychotic patients presented opportunities for many insights pertaining to the 
expressions of the disorder. Some patients failed on every given cognitive test, 
while others passed with flying colors. What were the factors contributing to the 
observed variance in the patients’ test performances and what were the possible 
consequences for the functional roles that each patient maintained in his/her 
everyday life? The resulting association could not possibly be a linear function. 
Some of the patients, who had great difficulties with the tests, had, with support 
from family, friends and communal service, enjoyed an active life that they were 
fully satisfied with. Thus, cognitive prowess seems not to be a necessary 
prerequisite, and does not need to predict the patient’s subjective quality of life; nor 
is it necessarily related to vocational outcome. For example, one young man with 
excellent cognitive performance had to have his case manager wake him up in the 
morning and drive him to the workplace, thereby posing questions regarding 
general functionality. Society offers very few job opportunities to people with 
chronic mental illness, and most patients cannot compete on the open work market. 
What is their greatest hindrance? 
 
 It seems to be the case, increasingly, that stress, both as vulnerability and 
precipitating factor, constitutes a major obstacle for schizopsychotic patients. 
Taking a test at the outpatient clinic is a rare and well-structured situation in which 
the patients can take all the time they need on tests that are not time-limited. The 
atmosphere is benevolent and supportive, and no matter what the results are, the 
patient gets credit for having gone through the testing. Nevertheless, under constant 
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time pressure or multiple demands, the schizopsychotic patient’s brain appears to 
be susceptible to strain, which taxes its capacity for optimal function. 
 Due to inherited or acquired deficits, the schizopsychotic patient’s brain is 
vulnerable to external and internal stress. Possibly, the notion of “vulnerability” 
constitutes the underlying general deficit that neuroscientists and clinicians have 
been searching for with the diligence of the ‘quest for the Holy Grail’. 
Vulnerability is, after all, a non-specific constellation of deficits whose presence is 
noted indirectly by a lower threshold for symptom manifestation and/or a higher 
threshold for adequate cognitive performance, both of which contribute to the 
expressions of disorder in the phenotype. These impairments may lead to global 
neurocognitive retardation in speed-related processing. Against this general 
background, different cognitive profiles may emerge. These profiles could be 
expected to covariate with the degree of experienced stress. Thus, the specific 
cognitive deficits profile for a given patient would be different when in a psychotic 
episode as opposed to while in remission. 
 
 In summary, neurocognitive functioning is an important factor to be considered 
in planning the treatment of schizopsychotic patients and, following current 
notions, the clinical staging of the disorder. Further research should focus on 
studying longitudinal cognitive profiles of schizopsychotic patients in order to 
determine which functions remain stable and which domains vary as a function of 
the ‘waxing and waning’ of the psychotic disorder.  
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